June 2025
Recently, CLL Society submitted a comment letter to the Centers for Medicare and Medicaid Services (“CMS”) addressing its questions on whether Breyanzi qualifies for a New Technology Add-On Payment (NTAP) under Medicare’s inpatient hospital payment system. CLL Society is concerned that CMS may not fully understand the challenges our patients face and the importance of new treatment lines for those who have exhausted available options. Without NTAPs, hospitals absorb the costs of providing new treatments. These added payments help ensure inpatient access to these therapies. As the latest CLL treatment under consideration for NTAP, we urged CMS to focus its inquiries regarding “newness” and “significant improvement” on the facts that (1) Breyanzi provides an additional line of treatment and (2) its progression-free survival benefit and/or extended time to the next treatment represent an added benefit, rather than a comparison to other therapies and treatment lines.
Read the full comment letter here.
